<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574209</url>
  </required_header>
  <id_info>
    <org_study_id>CD5X1000</org_study_id>
    <nct_id>NCT01574209</nct_id>
  </id_info>
  <brief_title>Gut Peptides and Intestinal Permeability in Celiac Disease and Irritable Bowel Syndrome</brief_title>
  <acronym>PPCD</acronym>
  <official_title>Gut Peptides and Intestinal Permeability in Celiac Patients, Healthy Subjects and IBS Patients: a Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that the intestinal barrier is altered in celiac disease (CD), an autoimmune
      disease that develops in genetically predisposed subjects exposed to ingestion of wheat
      gliadin and of related prolamines of barley and rye. More recently, defective epithelial
      barrier has been implicated in the pathogenesis of other conditions such as irritable bowel
      syndrome (IBS). At present IBS is still considered a functional condition although low-grade
      inflammation has been associated with its manifestation, particularly that following
      infection. Different substances have been implicated in the (dis)regulation of intestinal
      barrier, among them zonulin seems to play a key role. Other gastrointestinal peptides are
      GPL-2, Ghrelin, and Epidermal growth factor (EGF). In order to shed light on the hormonal
      regulation of intestinal barrier function in celiac patients before undergoing a gluten free
      diet and possible differences with those of IBS patients, in the present study the
      investigators will apply the non-invasive lactulose/mannitol permeability test toward the
      evaluation of intestinal damage. The pattern of intestinal permeability and the GI peptides
      concentration will be compared in celiac patients, IBS patients and healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of GI peptides (Zonulin, GLP-2, Ghrelin and EGF)</measure>
    <time_frame>within one month after the enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>within one month after the enrollment</time_frame>
    <description>The detection and measurement of two sugar probes, lactulose (La) and mannitol (Ma), in the urine will be performed by chromatographic analysis. For each sample the percentage of ingested La and Ma in urine will be evaluated and their ratio (La-Ma) will be calculated.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Celiac Disease</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Celiac Disease</arm_group_label>
    <description>Patients suffering from coeliac diseases confirmed by small intestinal biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBS patients</arm_group_label>
    <description>Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Healthy subjects as control group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients recruited in IRCCS &quot;S. de Bellis&quot;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria of celiac disease patients:

          -  Diagnosis of CD was based on the detection of IgA antiendomysial and IgA antitissue
             transglutaminase antibodies in serum

          -  Diagnosis must be confirmed by a small intestinal biopsy obtained at the time of
             gastrointestinal endoscopy.

          -  All patients must show Marsh 3 grade villous atrophy at the time of the diagnosis.

        Inclusion criteria of IBS patients.

          -  Subjects suffering from irritable bowel syndrome according to the Rome III criteria.

          -  Availability of at least one GI imaging study during the last five years (colonoscopy,
             sigmoidoscopy, abdominal ultrasound, barium enema)

        Exclusion criteria for both the above groups:

          -  None were taking anti-inflammatory drugs (including mast cell stabilisers, histamine
             antagonists, anticholinergics, anti-diarrhoea medication, probiotics,
             immunosuppressants and steroids)

          -  Presence of organic syndrome, including food allergy, atopy and severe clinical
             depression or anxiety.

          -  Abnormal laboratory data or thyroid function

          -  Major abdominal surgery Healthy subjects will be recruited in the administrative staff
             of the Institute after thorough exclusion of GI symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Riezzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Digestive Diseases IRCCS &quot;S. de Bellis&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Digestive Diseases IRCCS &quot;S. de Bellis&quot;</name>
      <address>
        <city>Castellana Grotte</city>
        <state>Bari</state>
        <zip>70013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011 Jan;91(1):151-75. doi: 10.1152/physrev.00003.2008. Review.</citation>
    <PMID>21248165</PMID>
  </reference>
  <reference>
    <citation>Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009 Aug;58(8):1091-103. doi: 10.1136/gut.2008.165886. Epub 2009 Feb 24.</citation>
    <PMID>19240062</PMID>
  </reference>
  <reference>
    <citation>Gecse K, Róka R, Séra T, Rosztóczy A, Annaházi A, Izbéki F, Nagy F, Molnár T, Szepes Z, Pávics L, Bueno L, Wittmann T. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion. 2012;85(1):40-6. doi: 10.1159/000333083. Epub 2011 Dec 14.</citation>
    <PMID>22179430</PMID>
  </reference>
  <reference>
    <citation>Ménard S, Lebreton C, Schumann M, Matysiak-Budnik T, Dugave C, Bouhnik Y, Malamut G, Cellier C, Allez M, Crenn P, Schulzke JD, Cerf-Bensussan N, Heyman M. Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol. 2012 Feb;180(2):608-15. doi: 10.1016/j.ajpath.2011.10.019. Epub 2011 Nov 24.</citation>
    <PMID>22119716</PMID>
  </reference>
  <reference>
    <citation>Malandrino N, Capristo E, Farnetti S, Leggio L, Abenavoli L, Addolorato G, Gasbarrini G. Metabolic and nutritional features in adult celiac patients. Dig Dis. 2008;26(2):128-33. doi: 10.1159/000116770. Epub 2008 Apr 21. Review.</citation>
    <PMID>18431062</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis</investigator_affiliation>
    <investigator_full_name>Giuseppe Riezzo</investigator_full_name>
    <investigator_title>Director of Experimental Pathophysiology Laboratory</investigator_title>
  </responsible_party>
  <keyword>Celiac disease</keyword>
  <keyword>IBS</keyword>
  <keyword>Intestinal barrier</keyword>
  <keyword>Intestinal permeability</keyword>
  <keyword>GI peptides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

